ESR1 and breast carcinoma: In estrogen receptor (ER)-positive breast cancer, resistance to therapies like tamoxifen and aromatase inhibitors often arises from mutations in ERα, such as ERαY537S and ERαD538G, which contribute to more aggressive metastatic disease that is less responsive to standard treatments (48).